Bright Minds Biosciences Inc. Share Price
Equities
DRUG
CA10919W4056
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.50 CAD | 0.00% |
|
+0.19% | -6.28% |
| 02-13 | Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 | CI |
| 01-09 | Bright Minds Biosciences Closes its US$175 Million Public Offering | MT |
| Capitalization | 1.01B 743M 627M 572M 545M 67.48B 1.05B 6.65B 2.64B 32.49B 2.79B 2.73B 114B | P/E ratio 2026 * |
-14.8x | P/E ratio 2027 * | -8.1x |
|---|---|---|---|---|---|
| Enterprise value | 1.01B 743M 627M 572M 545M 67.48B 1.05B 6.65B 2.64B 32.49B 2.79B 2.73B 114B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
72.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | +0.19% | ||
| Current month | -3.69% | ||
| 1 month | -15.78% | ||
| 3 months | +27.32% | ||
| 6 months | +72.62% | ||
| Current year | -6.28% |
| 1 week | 103.42 |  | 110.02 |
| 1 month | 100 | | 125.39 |
| Current year | 98.94 | | 170 |
| 1 year | 33.01 | | 170 |
| 3 years | 1.29 | | 170 |
| 5 years | 1.29 | | 170 |
| 10 years | 1.29 | | 170 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ian McDonald
CEO | Chief Executive Officer | 38 | 04/06/2020 |
Ryan Cheung
DFI | Director of Finance/CFO | 47 | 28/05/2020 |
| Chief Tech/Sci/R&D Officer | - | 06/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeremy Fryzuk
BRD | Director/Board Member | 40 | 28/09/2020 |
Nils Bottler
BRD | Director/Board Member | 38 | 28/09/2020 |
Ian McDonald
BRD | Director/Board Member | 38 | 30/05/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +0.19% | +71.05% | +2,034.02% | 743M | |
| +1.19% | +2.21% | -11.45% | -5.01% | 48.11B | |
| -0.10% | -0.80% | +49.90% | +47.04% | 38.3B | |
| -0.21% | +3.48% | +36.90% | +65.22% | 36.12B | |
| -1.13% | -13.35% | -13.70% | -25.47% | 28.31B | |
| -1.05% | -0.44% | +136.81% | +277.98% | 18.62B | |
| +7.58% | +12.65% | +31,531.21% | +4,286.06% | 15.44B | |
| -1.37% | -3.96% | +29.40% | -5.14% | 13.51B | |
| -0.82% | -2.57% | +50.14% | +94.25% | 13.28B | |
| -1.44% | -4.94% | +159.66% | +111.49% | 13.06B | |
| Average | +0.26% | -0.82% | +3,203.99% | +688.04% | 22.55B | |
| Weighted average by Cap. | +0.28% | -0.61% | +2,194.57% | +348.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -73.23M -53.73M -45.32M -41.34M -39.41M -4.88B -75.97M -480M -191M -2.35B -201M -197M -8.25B | -180M -132M -111M -102M -96.79M -11.98B -187M -1.18B -469M -5.77B -495M -485M -20.25B |
| Net Debt | - | - |
Employees
26
Calendar
03-30
- Annual General Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 103.50 $ | -4.75% | 453 |
| 12/02/26 | 108.66 $ | +3.03% | 215 |
| 11/02/26 | 105.46 $ | +2.09% | 405 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
103.50CAD
Average target price
117.00CAD
Spread / Average Target
+13.04%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DRUG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition